The facilitation undergoes activity-dependent enhancement that is thought to contribute to classical conditioning of the gill- and siphon-withdrawal reflex.
In TNK-pre-treated patients without reperfusion (TIMI 0-1) after PCI, NT-proBNP levels at Day 7 or 90 were not significantly higher than in PCI patients.Baseline NT-proBNP predicts outcome at 90 days and 1 year in patients undergoing PCI with or without facilitation with TNK.
Nevertheless, this is the first demonstration of mortality benefits from pharmacological facilitation in STEMI patients undergoing primary angioplasty and indicates a need for further studies to identify the best strategy.
8 9 The ASSENT-4 trial 30 showed harmful effects from facilitation with full-dose tenecteplase in patients undergoing primary angioplasty, despite improved preprocedural recanalisation.
8 9 The Early Glycoprotein IIb IIIa Inhibitors in Primary Angioplasty (EGYPT) cooperation aimed at performing a comprehensive meta-analysis of randomised trials based on individual patient data to evaluate the benefits of pharmacological facilitation with Gp IIb IIIa inhibitors in patients undergoing primary angioplasty for STEMI.
These synapses have a unique ability to tune synaptic transmission to a wide range of firing frequencies, the prevailing physiological range being about 0.5 4 Hz (Bischofberger et al. 2006), whereby responses can undergo a pronounced frequency facilitation (Salin et al. 1996).
This meta-analysis shows that pharmacological facilitation with the early administration of Gp IIb IIIa inhibitors in patients undergoing primary angioplasty for STEMI is associated with significant benefits in terms of preprocedural epicardial recanalisation and ST-segment resolution, which translated into non-significant mortality benefits except for abciximab.
Volcanology has been undergoing a fundamental transformation over the past 10 15 years brought about by the internet's facilitation of access to large volumes of information, greater community acceptance of computational modeling and statistical analysis, and increased attention to volcanic hazards.
Therefore, until the results of additional large randomised trials with long-term follow-up data become available, pharmacological facilitation with Gp IIb IIIa inhibitor administration, particularly abciximab, may be considered in patients undergoing primary angioplasty for STEMI.
We identified all randomised trials comparing pharmacological facilitation by the early administration of Gp IIb IIIa inhibitors versus its periprocedural administration in STEMI patients undergoing primary angioplasty.
